Assisted Human Reproduction Unit, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.
Biotechnology Department, Alicante University, 03690 Alicante, Spain.
Int J Mol Sci. 2021 Jan 23;22(3):1125. doi: 10.3390/ijms22031125.
The combination of in vitro maturation (IVM) techniques and oocyte vitrification (OV) could increase the number of useful oocytes in different types of patients. IVM and subsequent OV is the most widely used clinical strategy. Would the results improve if we reverse the order of the techniques? Here, we evaluated survival, in vitro maturation, time to extrude the first polar body (PB), and the metaphase plate configuration of human prophase I (GV) oocytes before or after their vitrification. Specific, 195 GV oocytes from 104 patients subjected to controlled ovarian stimulation cycles were included. We stablished three experimental groups: GV oocytes vitrified and IVM (Group GV-Vit), GV oocytes IVM and vitrified at MII stage (Group MII-Vit), and GV oocytes IVM (Group not-Vit). All of them were in vitro matured for a maximum of 48 h and fixed to study the metaphase plate by confocal microscopy. According to our results, the vitrification of immature oocytes and their subsequent maturation presented similar survival, maturation, and metaphase plate conformation rates, but a significantly higher percentage of normal spindle than the standard strategy. Additionally, the extension of IVM time to 48 h did not seem to negatively affect the oocyte metaphase plate configuration.
体外成熟 (IVM) 技术与卵母细胞玻璃化 (OV) 的结合可以增加不同类型患者中有用卵母细胞的数量。IVM 及随后的 OV 是最广泛应用的临床策略。如果我们反转技术的顺序，结果会改善吗？在这里，我们评估了人类前期 I 期 (GV) 卵母细胞在玻璃化之前或之后的存活、体外成熟、首次极体 (PB) 挤出时间和中期板构型。共纳入 104 例接受控制性卵巢刺激周期的患者的 195 个 GV 卵母细胞。我们建立了三个实验组：GV 卵母细胞玻璃化和 IVM（GV-Vit 组）、GV 卵母细胞 IVM 并在 MII 期玻璃化（MII-Vit 组）和 GV 卵母细胞 IVM（未 Vit 组）。所有卵母细胞都进行了最长 48 小时的体外成熟，并通过共聚焦显微镜固定以研究中期板。根据我们的结果，不成熟卵母细胞的玻璃化及其随后的成熟呈现出相似的存活率、成熟率和中期板构象率，但正常纺锤体的比例明显高于标准策略。此外，将 IVM 时间延长至 48 小时似乎不会对卵母细胞中期板构型产生负面影响。
